Oxxon Therapeutics Limited
Records under this name other than patents Oxxon Therapeutics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Oxxon Therapeutics Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,407,661 | Methods and reagents that generate a CD8 T cell immune response Term ended Term ended Dec 1, 2018 · USPTO record | Term ended | Term ended Dec 1, 2018 | USPTO record |
| US 7,514,087 | Methods and reagents for immunization which generate a CD8 T cell immune response Term ended Term ended Sep 5, 2018 · USPTO record | Term ended | Term ended Sep 5, 2018 | USPTO record |
| US 6,663,871 | Methods and reagents for vaccination which generate a CD8 T cell immune response Formerly held Term ended Term ended Jun 9, 2018 · USPTO record | Term ended | Term ended Jun 9, 2018 | USPTO record |
| US 7,384,643 | Recombinant poxvirus Lapsed on the fee record Ended Jun 10, 2012 · USPTO record | Lapsed on the fee record | Ended Jun 10, 2012 | USPTO record |
| US 6,355,252 | Soluble vaccinia virus protein that binds chemokines Lapsed on the fee record Ended Mar 12, 2010 · USPTO record | Lapsed on the fee record | Ended Mar 12, 2010 | USPTO record |
| US 5,972,351 | Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens Term ended Term ended no later than Oct 26, 2019 · Low confidence | Term ended | Term ended no later than Oct 26, 2019 | Low confidence |